Paul H Huang

List of Publications by Year
in descending order

96 papers	4,216 citations	159585 30 h-index	123424 61 g-index
103 all docs	103 docs citations	103 times ranked	6393 citing authors

#	Article	IF	Citations
1	Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 12867-12872.	7.1	365
2	Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Seminars in Cancer Biology, 2020, 61, 167-179.	9.6	302
3	Oncogenic EGFR Signaling Networks in Glioma. Science Signaling, 2009, 2, re6.	3.6	299
4	Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduction and Targeted Therapy, 2019, 4, 5.	17.1	231
5	14-3-3Ïƒ controls mitotic translation to facilitate cytokinesis. Nature, 2007, 446, 329-332.	27.8	217
6	Clinical and Molecular Spectrum of Liposarcoma. Journal of Clinical Oncology, 2018, 36, 151-159.	1.6	183
7	Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated Signaling. Journal of Biological Chemistry, 2013, 288, 7430-7437.	3.4	182
8	Receptor Tyrosine Kinase Coactivation Networks in Cancer. Cancer Research, 2010, 70, 3857-3860.	0.9	161
9	Discoidin Domain Receptors Promote Î±1Î²1- and Î±2Î²1-Integrin Mediated Cell Adhesion to Collagen by Enhancing Integrin Activation. PLoS ONE, 2012, 7, e52209.	2.5	122
10	The Pathobiology of Collagens in Glioma. Molecular Cancer Research, 2013, 11, 1129-1140.	3.4	121
11	Future Directions in the Treatment of Osteosarcoma. Cells, 2021, 10, 172.	4.1	102
12	Novel therapeutic approaches in chondrosarcoma. Future Oncology, 2017, 13, 637-648.	2.4	96
13	Data-independent acquisition mass spectrometry (DIA-MS) for proteomic applications in oncology. Molecular Omics, 2021, 17, 29-42.	2.8	93
14	Primary Cilia Mediate Diverse Kinase Inhibitor Resistance Mechanisms in Cancer. Cell Reports, 2018, 23, 3042-3055.	6.4	77
15	SWATH mass spectrometry as a tool for quantitative profiling of the matrisome. Journal of Proteomics, 2018, 189, 11-22.	2.4	75
16	Phosphoproteomics of collagen receptor networks reveals SHP-2 phosphorylation downstream of wild-type DDR2 and its lung cancer mutants. Biochemical Journal, 2013, 454, 501-513.	3.7	68
17	Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. ESMO Open, 2021, 6, 100170.	4.5	65
18	Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. Cell Cycle, 2007, 6, 2750-2754.	2.6	63

#	Article	IF	Citations
19	Direct Involvement of Retinoblastoma Family Proteins in DNA Repair by Non-homologous End-Joining. Cell Reports, 2015, 10, 2006-2018.	6.4	62
20	EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene, 2010, 29, 5850-5860.	5.9	58
21	Fibroblastic Reticular Cells Control Conduit Matrix Deposition during Lymph Node Expansion. Cell Reports, 2019, 29, 2810-2822.e5.	6.4	58
22	Pazopanib in advanced soft tissue sarcomas. Signal Transduction and Targeted Therapy, 2019, 4, 16.	17.1	57
23	A HIF-Regulated VHL-PTP1B-Src Signaling Axis Identifies a Therapeutic Target in Renal Cell Carcinoma. Science Translational Medicine, 2011, 3, 85ra47.	12.4	54
24	Phosphoproteomics: Unraveling the Signaling Web. Molecular Cell, 2008, 31, 777-781.	9.7	50
25	Proteomic research in sarcomas â€" current status and future opportunities. Seminars in Cancer Biology, 2020, 61, 56-70.	9.6	50
26	Dual Targeting of PDGFRÎ± and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. Cell Reports, 2016, 17, 1265-1275.	6.4	44
27	Comparative proteomic assessment of matrisome enrichment methodologies. Biochemical Journal, 2016, 473, 3979-3995.	3.7	41
28	Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Molecular BioSystems, 2010, 6, 1227.	2.9	40
29	Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 900-904.	1.1	40
30	Threeâ€dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic <scp>MCF10</scp> model. Journal of Pathology, 2016, 240, 315-328.	4.5	35
31	Phosphoproteomics in translational research: a sarcoma perspective. Annals of Oncology, 2016, 27, 787-794.	1.2	34
32	Glycosylation at Asn211 Regulates the Activation State of the Discoidin Domain Receptor 1 (DDR1). Journal of Biological Chemistry, 2014, 289, 9275-9287.	3.4	33
33	The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib. Expert Review of Anticancer Therapy, 2019, 19, 971-991.	2.4	31
34	Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discovery Today, 2017, 22, 72-84.	6.4	30
35	Discoidin domain receptors: a proteomic portrait. Cellular and Molecular Life Sciences, 2014, 71, 3269-3279.	5.4	28
36	An integrated comparative phosphoproteomic and bioinformatic approach reveals a novel class of MPM-2 motifs upregulated in EGFRvIII-expressing glioblastoma cells. Molecular BioSystems, 2009, 5, 59-67.	2.9	27

#	Article	IF	Citations
37	Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib. Journal of Proteomics, 2018, 170, 130-140.	2.4	27
38	Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation. Cell Adhesion and Migration, 2013, 7, 161-164.	2.7	26
39	Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer. Oncotarget, 2016, 7, 62939-62953.	1.8	26
40	Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays in Biochemistry, 2018, 62, 583-593.	4.7	25
41	Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas. Npj Precision Oncology, 2021, 5, 17.	5.4	23
42	The adequacy of tissue microarrays in the assessment of inter- and intra-tumoural heterogeneity of infiltrating lymphocyte burden in leiomyosarcoma. Scientific Reports, 2019, 9, 14602.	3.3	22
43	Targeting the Fibroblast Growth Factor Receptor (FGFR) Family in Lung Cancer. Cells, 2021, 10, 1154.	4.1	21
44	Is the IDH Mutation a Good Target for Chondrosarcoma Treatment?. Current Molecular Biology Reports, 2020, 6, 1-9.	1.6	20
45	Phase III Soft Tissue Sarcoma Trials: Success or Failure?. Current Treatment Options in Oncology, 2017, 18, 19.	3.0	19
46	Unmet Medical Needs and Future Perspectives for Leiomyosarcoma Patientsâ€"A Position Paper from the National LeioMyoSarcoma Foundation (NLMSF) and Sarcoma Patients EuroNet (SPAEN). Cancers, 2021, 13, 886.	3.7	17
47	Olaratumab in soft tissue sarcoma â€" Current status and future perspectives. European Journal of Cancer, 2018, 92, 33-39.	2.8	16
48	A mouse SWATH-MS reference spectral library enables deconvolution of species-specific proteomic alterations in human tumour xenografts. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	16
49	Advances in the proteomic profiling of the matrisome and adhesome. Expert Review of Proteomics, 2021, 18, 781-794.	3.0	16
50	Phosphoproteomic studies of receptor tyrosine kinases: future perspectives. Molecular BioSystems, 2012, 8, 1100-1107.	2.9	15
51	Optimal Clinical Management and the Molecular Biology of Angiosarcomas. Cancers, 2020, 12, 3321.	3.7	15
52	Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. Future Oncology, 2021, 17, 3627-3636.	2.4	15
53	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. Journal of Molecular Biology, 2017, 429, 1767-1786.	4.2	14
54	Fibroblast Growth Factor Receptor (FGFR) Signaling in GIST and Soft Tissue Sarcomas. Cells, 2021, 10, 1533.	4.1	14

#	Article	IF	Citations
55	Advances in mass spectrometry based strategies to study receptor tyrosine kinases. IUCrJ, 2017, 4, 119-130.	2.2	13
56	Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma. Expert Opinion on Investigational Drugs, 2019, 28, 505-511.	4.1	13
57	Next-generation sequencing for the management of sarcomas with no known driver mutations. Current Opinion in Oncology, 2021, 33, 315-322.	2.4	13
58	Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry. Journal of Proteomics, 2021, 241, 104236.	2.4	12
59	RB in DNA repair. Oncotarget, 2015, 6, 20746-20747.	1.8	12
60	Melanoma troops massed. Nature, 2009, 459, 336-337.	27.8	11
61	Targeting SWI/SNF mutant cancers with tyrosine kinase inhibitor therapy. Expert Review of Anticancer Therapy, 2017, 17, 1-3.	2.4	11
62	Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. International Journal of Molecular Sciences, 2020, 21, 3214.	4.1	11
63	Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer. Pharmacogenomics and Personalized Medicine, 2021, Volume 14, 301-317.	0.7	11
64	Systemic treatment of advanced clear cell sarcoma: results from a retrospective international series from the World Sarcoma Network. ESMO Open, 2022, 7, 100522.	4.5	11
65	KIT Exon 9-Mutated Gastrointestinal Stromal Tumours: Biology and Treatment. Chemotherapy, 2022, 67, 81-90.	1.6	10
66	Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas. Current Treatment Options in Oncology, 2022, 23, 78-88.	3.0	10
67	Tropomyosin receptor kinase inhibitors in the management of sarcomas. Current Opinion in Oncology, 2020, 32, 307-313.	2.4	9
68	Clinical management and outcomes of primary ovarian leiomyosarcoma â€“ Experience from a sarcoma specialist unit. Gynecologic Oncology Reports, 2021, 36, 100737.	0.6	9
69	Amivantamab for the treatment of<i>EGFR</i>exon 20 insertion mutant non-small cell lung cancer. Expert Review of Anticancer Therapy, 2022, 22, 3-16.	2.4	9
70	Machine learning for rhabdomyosarcoma histopathology. Modern Pathology, 2022, 35, 1193-1203.	5.5	9
71	Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas. Biomedicines, 2022, 10, 573.	3.2	8
72	Alterations in the phosphoproteomic profile of cells expressing a non-functional form of the SHP2 phosphatase. New Biotechnology, 2016, 33, 524-536.	4.4	7

#	Article	IF	Citations
73	3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 847-859.	0.9	7
74	Avapritinib in the treatment of PDGFRA exon 18 mutated gastrointestinal stromal tumors. Future Oncology, 2020, 16, 1641-1648.	2.4	7
75	EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma. Cancers, 2022, 14, 394.	3.7	7
76	The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling. Frontiers in Cell and Developmental Biology, 2021, 9, 763640.	3.7	7
77	Pharmacotherapy for liposarcoma: current and emerging synthetic treatments. Future Oncology, 2021, 17, 2659-2670.	2.4	6
78	Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?. Frontiers in Oncology, 0, 12, .	2.8	6
79	Retinoblastoma family proteins: New players in DNA repair by non-homologous end-joining. Molecular and Cellular Oncology, 2016, 3, e1053596.	0.7	5
80	Drug repositioning in sarcomas and other rare tumors. EBioMedicine, 2016, 6, 4-5.	6.1	4
81	The perplexing role of immuno-oncology drugs in osteosarcoma. Journal of Bone Oncology, 2021, 31, 100400.	2.4	4
82	Expanding the computational toolbox for interrogating cancer kinomes. Pharmacogenomics, 2016, 17, 95-97.	1.3	3
83	Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue. Anticancer Research, 2020, 40, 7003-7007.	1.1	3
84	Sirolimus for patients with progressive epithelioid hemangioendothelioma. Cancer, 2021, 127, 504-506.	4.1	3
85	Gastrointestinal leiomyosarcoma demonstrate a predilection for distant recurrence and poor response to systemic treatments. European Journal of Surgical Oncology, 2021, 47, 2595-2601.	1.0	3
86	Targeted Analysis of Phosphotyrosine Signaling by Multiple Reaction Monitoring Mass Spectrometry. Methods in Molecular Biology, 2017, 1636, 263-281.	0.9	3
87	Dacomitinib. Drugs of the Future, 2012, 37, 393.	0.1	3
88	Spatial localisation of Discoidin Domain Receptor 2 (DDR2) signalling is dependent on its collagen binding and kinase activity. Biochemical and Biophysical Research Communications, 2018, 501, 124-130.	2.1	2
89	Proteomic Profiling Identifies Co-Regulated Expression of Splicing Factors as a Characteristic Feature of Intravenous Leiomyomatosis. Cancers, 2022, 14, 2907.	3.7	2
90	Negative phase III trials announce the need for biomarkers in sarcoma. European Journal of Cancer, 2019, 123, 81-82.	2.8	1

#	Article	IF	Citations
91	Analysis of Phosphotyrosine Signaling Networks in Lung Cancer Cell Lines. Methods in Molecular Biology, 2017, 1636, 253-262.	0.9	1
92	Progress and impact of clinical phosphoproteomics on precision oncology. Translational Cancer Research, 2017, 6, S1108-S1114.	1.0	1
93	Combinatorial Therapeutic Strategies for Blocking Kinase Pathways in Brain Tumors. , 2009, , 953-975.		1
94	Ewing-like sarcomas: New molecular diagnoses in need of optimized treatment approaches. Indian Journal of Medical Research, 2019, 150, 521.	1.0	1
95	Discoidin Domain Receptor Signalling Networks. , 2016, , 201-216.		0
96	Translational genomics for rare cancers: Challenges and opportunity. Seminars in Cancer Biology, 2020, 61, iii-iv.	9.6	0